Skip to content

Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525669-33-00
Enrollment
15
Registered
2026-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic postsurgical pain (CPSP)

Brief summary

Inclusion of a minimum of 15 participants within the study period., Determination of percentage of patients eligible for recruitment who are enrolled and the rate of enrolment., Recording of reasons for declining study participation, if possible., Determination of percentage of completion.

Detailed description

Testing of practical feasibility of the administration method by subcutaneous BTX-A injections in the chest wall evaluated by the percentages of participants completing the intended intervention., Evaluation of tolerability of the intervention during administration and possible side effects/adverse events during follow-up., Determination of questionnaire completion and participation rates at each follow-up assessment time point., Evaluation of “proof of concept” for subcutaneous BTX-A as pain relief in chronic postsurgical pain following surgery for lung cancer, specifically.

Interventions

Sponsors

Aalborg University Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Inclusion of a minimum of 15 participants within the study period., Determination of percentage of patients eligible for recruitment who are enrolled and the rate of enrolment., Recording of reasons for declining study participation, if possible., Determination of percentage of completion.

Secondary

MeasureTime frame
Testing of practical feasibility of the administration method by subcutaneous BTX-A injections in the chest wall evaluated by the percentages of participants completing the intended intervention., Evaluation of tolerability of the intervention during administration and possible side effects/adverse events during follow-up., Determination of questionnaire completion and participation rates at each follow-up assessment time point., Evaluation of “proof of concept” for subcutaneous BTX-A as pain relief in chronic postsurgical pain following surgery for lung cancer, specifically.

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 2, 2026